(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott today released the following statement on the Senate Finance Committee hearing, “Drug Pricing in America: A Prescription for Change, Part III:” “We applaud the Senate Finance Committee
PBM Principles on Patient Access to Prescription Drugs During the COVID-19 Pandemic During this public health emergency, PBMs are committed to helping the patients we serve practice social distancing and stay at home safely with convenient, reliable access to their
A recent white paper (“The Association Between Drug Rebates and List Prices”) narrowly suggests an association between list prices for brand drugs and the rebate practices of pharmacy benefit managers (PBMs) and insurers, despite an underlying methodology that is notably broader
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a new report from the IQVIA Institute that shows net prescription spending is decreasing in settings in which pharmacy benefit management (PBM) tools are widely used.
(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s action in the House Judiciary Committee on legislation aimed at increasing competition in the prescription drug marketplace. “We applaud the House Judiciary
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Biden Administration’s announcement to curb drug manufacturer patent abuses. “We applaud the Biden Administration for taking real action to reduce prescription
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re highlighting new reputable third-party research and analyses by economists which underscore that legislation focused on
In case you missed it, the Pharmaceutical Care Management Association (PCMA) released a new Rx Research Corner blog, by Vice President of Research Amanda Frost, that quantifies what a world without pharmacy benefit companies would look like for employers and
With so many important issues being debated today, there are few topics that health care, legal, and economic experts agree on. But the fact that drug companies are the root cause of high prescription drug prices is one common denominator
(Washington D.C.) – Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s Senate Finance Committee hearing, “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare.” “PCMA commends the Senate Finance Committee
©2024 PCMA. All Rights Reserved.
